CD274 and neoplasm: MDSCs have widely demonstrated that they are capable of producing changes in the tumour microenvironment, promoting the development and progression of oncological disease; but probably the most important role today is resistance to checkpoint inhibitor treatments such as anti-PD-1 and anti-PD-L1.